Engineered therapeutic antibodies with improved effector functions
In the past decade, more than 20 therapeutic antibodies have been approved for clinical use and many others are now at the clinical and preclinical stage of development. Fragment crystallizable (Fc)‐dependent antibody functions, such as antibody‐dependent cell‐mediated cytotoxicity (ADCC), complemen...
Gespeichert in:
| Veröffentlicht in: | Cancer science 2009-09, Vol.100 (9), p.1566-1572 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1572 |
|---|---|
| container_issue | 9 |
| container_start_page | 1566 |
| container_title | Cancer science |
| container_volume | 100 |
| creator | Kubota, Tsuguo Niwa, Rinpei Satoh, Mitsuo Akinaga, Shiro Shitara, Kenya Hanai, Nobuo |
| description | In the past decade, more than 20 therapeutic antibodies have been approved for clinical use and many others are now at the clinical and preclinical stage of development. Fragment crystallizable (Fc)‐dependent antibody functions, such as antibody‐dependent cell‐mediated cytotoxicity (ADCC), complement‐dependent cytotoxicity (CDC), and a long half‐life, have been suggested as important clinical mechanisms of therapeutic antibodies. These functions are primarily triggered through direct interaction of the Fc domain with its corresponding receptors: FcγRIIIa for ADCC, C1q for CDC, and neonatal Fc receptor for prolongation of the clearance rate. However, current antibody therapy still faces the critical issues of insufficient efficacy and the high cost of the therapeutic agents. A possible solution to these issues could be to engineer antibody molecules to enhance their antitumor activity, leading to improved therapeutic outcomes and reduced doses. Here, we review advanced Fc engineering approaches for the enhancement of effector functions, some of which are now ready for evaluation of their effectiveness in clinical trials. (Cancer Sci 2009; 100: 1566–1572) |
| doi_str_mv | 10.1111/j.1349-7006.2009.01222.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11159150</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67602238</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5372-3a7bab82d9d7f91182a78a7bd6d3d84ed83317f32bae87e21110231e7f1405033</originalsourceid><addsrcrecordid>eNqNkUtvEzEUhS0Eom3gL6DZwG4GPyZje4FQG5WCVIkFsLY89nXjaGIHe6aPf48niQKswBtf-X73-B4dhCqCG1LO-01DWCtrjnHXUIxlgwmltHl8hs5Pjef7mtcSM3qGLnLeYMy6VrYv0RmRSyZayc_R1XW48wEgga3GNSS9g2n0ptJh9H20HnL14Md15be7FO8LBM6BGWOq3BTM6GPIr9ALp4cMr4_3Av34dP199bm-_XrzZXV5W5sl47Rmmve6F9RKy50kRFDNRXmznWVWtGAFY4Q7RnsNggMtPjFlBLgjLV5ixhbo40F3N_VbsAbCmPSgdslvdXpSUXv1dyf4tbqL96ooLSUpEgv07qiQ4s8J8qi2PhsYBh0gTll1vMOUMvFPkGIuW951BRQH0KSYcwJ3Wofg-V-iNmpORM2JqDkqtY9KPZbRN3_a-T14zKYAb4-AzkYPLulgfD5xlIiywd7VhwP34Ad4-u8F1Ory21yxX3jHr_w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20794766</pqid></control><display><type>article</type><title>Engineered therapeutic antibodies with improved effector functions</title><source>Wiley Online Library Open Access</source><creator>Kubota, Tsuguo ; Niwa, Rinpei ; Satoh, Mitsuo ; Akinaga, Shiro ; Shitara, Kenya ; Hanai, Nobuo</creator><creatorcontrib>Kubota, Tsuguo ; Niwa, Rinpei ; Satoh, Mitsuo ; Akinaga, Shiro ; Shitara, Kenya ; Hanai, Nobuo</creatorcontrib><description>In the past decade, more than 20 therapeutic antibodies have been approved for clinical use and many others are now at the clinical and preclinical stage of development. Fragment crystallizable (Fc)‐dependent antibody functions, such as antibody‐dependent cell‐mediated cytotoxicity (ADCC), complement‐dependent cytotoxicity (CDC), and a long half‐life, have been suggested as important clinical mechanisms of therapeutic antibodies. These functions are primarily triggered through direct interaction of the Fc domain with its corresponding receptors: FcγRIIIa for ADCC, C1q for CDC, and neonatal Fc receptor for prolongation of the clearance rate. However, current antibody therapy still faces the critical issues of insufficient efficacy and the high cost of the therapeutic agents. A possible solution to these issues could be to engineer antibody molecules to enhance their antitumor activity, leading to improved therapeutic outcomes and reduced doses. Here, we review advanced Fc engineering approaches for the enhancement of effector functions, some of which are now ready for evaluation of their effectiveness in clinical trials. (Cancer Sci 2009; 100: 1566–1572)</description><identifier>ISSN: 1347-9032</identifier><identifier>ISSN: 1349-7006</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/j.1349-7006.2009.01222.x</identifier><identifier>PMID: 19538497</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject>Animals ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - therapeutic use ; Biological and medical sciences ; Humans ; Medical sciences ; Neoplasms - therapy ; Protein Engineering ; Review ; Tumors</subject><ispartof>Cancer science, 2009-09, Vol.100 (9), p.1566-1572</ispartof><rights>2009 Japanese Cancer Association</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5372-3a7bab82d9d7f91182a78a7bd6d3d84ed83317f32bae87e21110231e7f1405033</citedby><cites>FETCH-LOGICAL-c5372-3a7bab82d9d7f91182a78a7bd6d3d84ed83317f32bae87e21110231e7f1405033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11159150/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11159150/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1349-7006.2009.01222.x$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21876650$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19538497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kubota, Tsuguo</creatorcontrib><creatorcontrib>Niwa, Rinpei</creatorcontrib><creatorcontrib>Satoh, Mitsuo</creatorcontrib><creatorcontrib>Akinaga, Shiro</creatorcontrib><creatorcontrib>Shitara, Kenya</creatorcontrib><creatorcontrib>Hanai, Nobuo</creatorcontrib><title>Engineered therapeutic antibodies with improved effector functions</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>In the past decade, more than 20 therapeutic antibodies have been approved for clinical use and many others are now at the clinical and preclinical stage of development. Fragment crystallizable (Fc)‐dependent antibody functions, such as antibody‐dependent cell‐mediated cytotoxicity (ADCC), complement‐dependent cytotoxicity (CDC), and a long half‐life, have been suggested as important clinical mechanisms of therapeutic antibodies. These functions are primarily triggered through direct interaction of the Fc domain with its corresponding receptors: FcγRIIIa for ADCC, C1q for CDC, and neonatal Fc receptor for prolongation of the clearance rate. However, current antibody therapy still faces the critical issues of insufficient efficacy and the high cost of the therapeutic agents. A possible solution to these issues could be to engineer antibody molecules to enhance their antitumor activity, leading to improved therapeutic outcomes and reduced doses. Here, we review advanced Fc engineering approaches for the enhancement of effector functions, some of which are now ready for evaluation of their effectiveness in clinical trials. (Cancer Sci 2009; 100: 1566–1572)</description><subject>Animals</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Neoplasms - therapy</subject><subject>Protein Engineering</subject><subject>Review</subject><subject>Tumors</subject><issn>1347-9032</issn><issn>1349-7006</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtvEzEUhS0Eom3gL6DZwG4GPyZje4FQG5WCVIkFsLY89nXjaGIHe6aPf48niQKswBtf-X73-B4dhCqCG1LO-01DWCtrjnHXUIxlgwmltHl8hs5Pjef7mtcSM3qGLnLeYMy6VrYv0RmRSyZayc_R1XW48wEgga3GNSS9g2n0ptJh9H20HnL14Md15be7FO8LBM6BGWOq3BTM6GPIr9ALp4cMr4_3Av34dP199bm-_XrzZXV5W5sl47Rmmve6F9RKy50kRFDNRXmznWVWtGAFY4Q7RnsNggMtPjFlBLgjLV5ixhbo40F3N_VbsAbCmPSgdslvdXpSUXv1dyf4tbqL96ooLSUpEgv07qiQ4s8J8qi2PhsYBh0gTll1vMOUMvFPkGIuW951BRQH0KSYcwJ3Wofg-V-iNmpORM2JqDkqtY9KPZbRN3_a-T14zKYAb4-AzkYPLulgfD5xlIiywd7VhwP34Ad4-u8F1Ory21yxX3jHr_w</recordid><startdate>200909</startdate><enddate>200909</enddate><creator>Kubota, Tsuguo</creator><creator>Niwa, Rinpei</creator><creator>Satoh, Mitsuo</creator><creator>Akinaga, Shiro</creator><creator>Shitara, Kenya</creator><creator>Hanai, Nobuo</creator><general>Blackwell Publishing Asia</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200909</creationdate><title>Engineered therapeutic antibodies with improved effector functions</title><author>Kubota, Tsuguo ; Niwa, Rinpei ; Satoh, Mitsuo ; Akinaga, Shiro ; Shitara, Kenya ; Hanai, Nobuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5372-3a7bab82d9d7f91182a78a7bd6d3d84ed83317f32bae87e21110231e7f1405033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Neoplasms - therapy</topic><topic>Protein Engineering</topic><topic>Review</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kubota, Tsuguo</creatorcontrib><creatorcontrib>Niwa, Rinpei</creatorcontrib><creatorcontrib>Satoh, Mitsuo</creatorcontrib><creatorcontrib>Akinaga, Shiro</creatorcontrib><creatorcontrib>Shitara, Kenya</creatorcontrib><creatorcontrib>Hanai, Nobuo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Kubota, Tsuguo</au><au>Niwa, Rinpei</au><au>Satoh, Mitsuo</au><au>Akinaga, Shiro</au><au>Shitara, Kenya</au><au>Hanai, Nobuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Engineered therapeutic antibodies with improved effector functions</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2009-09</date><risdate>2009</risdate><volume>100</volume><issue>9</issue><spage>1566</spage><epage>1572</epage><pages>1566-1572</pages><issn>1347-9032</issn><issn>1349-7006</issn><eissn>1349-7006</eissn><abstract>In the past decade, more than 20 therapeutic antibodies have been approved for clinical use and many others are now at the clinical and preclinical stage of development. Fragment crystallizable (Fc)‐dependent antibody functions, such as antibody‐dependent cell‐mediated cytotoxicity (ADCC), complement‐dependent cytotoxicity (CDC), and a long half‐life, have been suggested as important clinical mechanisms of therapeutic antibodies. These functions are primarily triggered through direct interaction of the Fc domain with its corresponding receptors: FcγRIIIa for ADCC, C1q for CDC, and neonatal Fc receptor for prolongation of the clearance rate. However, current antibody therapy still faces the critical issues of insufficient efficacy and the high cost of the therapeutic agents. A possible solution to these issues could be to engineer antibody molecules to enhance their antitumor activity, leading to improved therapeutic outcomes and reduced doses. Here, we review advanced Fc engineering approaches for the enhancement of effector functions, some of which are now ready for evaluation of their effectiveness in clinical trials. (Cancer Sci 2009; 100: 1566–1572)</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>19538497</pmid><doi>10.1111/j.1349-7006.2009.01222.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1347-9032 |
| ispartof | Cancer science, 2009-09, Vol.100 (9), p.1566-1572 |
| issn | 1347-9032 1349-7006 1349-7006 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11159150 |
| source | Wiley Online Library Open Access |
| subjects | Animals Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Biological and medical sciences Humans Medical sciences Neoplasms - therapy Protein Engineering Review Tumors |
| title | Engineered therapeutic antibodies with improved effector functions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T04%3A05%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Engineered%20therapeutic%20antibodies%20with%20improved%20effector%20functions&rft.jtitle=Cancer%20science&rft.au=Kubota,%20Tsuguo&rft.date=2009-09&rft.volume=100&rft.issue=9&rft.spage=1566&rft.epage=1572&rft.pages=1566-1572&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/j.1349-7006.2009.01222.x&rft_dat=%3Cproquest_24P%3E67602238%3C/proquest_24P%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20794766&rft_id=info:pmid/19538497&rfr_iscdi=true |